lumiracoxib (Prexige)
Jump to navigation
Jump to search
Introduction
approved in the UK, but not yet in the US.)[1][2][3]
Indications
Dosage
Adverse effects
- elevated serum transaminases
- lower risk of upper GI bleeding & small bowel injury than non-selective NSIADs[3]
Mechanism of action
- highly-selective cyclooxygenase-2/COX-2 inhibitor
More general terms
References
- ↑ 1.0 1.1 Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Matchaba P, Gimona A, Hawkey CJ; TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet. 2004 Aug 21;364(9435):665-74. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15325831
- ↑ 2.0 2.1 Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Gimona A, Matchaba P, Hawkey CJ, Chesebro JH; TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet. 2004 Aug 21;364(9435):675-84. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15325832
- ↑ 3.0 3.1 3.2 Journal Watch 24(19):149, 2004
- ↑ Hawkey CJ et al. Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole. Clin Gastroenterol Hepatol 2008 May; 6:536. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18242145